Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-106b-25 lentiviral vector
- Development stage
- Preclinical
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
miR-106b-25 lentiviral vector is a gene therapy research tool designed to overexpress the miR-106b-25 microRNA cluster, which comprises miR-106b, miR-93, and miR-25. In hematological malignancies such as Acute Myeloid Leukemia (AML), this cluster is implicated in promoting chemoresistance and disease progression by inhibiting multiple apoptotic pathways. The vector delivers the genetic sequence of the cluster into target cells, leading to the direct and indirect downregulation of pro-apoptotic genes, including TP73, BAK1, and CASPASE-7. This suppression of apoptosis enhances leukemic cell proliferation and confers resistance to various treatments, including doxorubicin, imatinib, and BCL-2 inhibitors. It is primarily utilized in preclinical research to investigate the biological roles of these microRNAs and to explore potential diagnostic and therapeutic strategies for AML.
- Other names
- miR-106b-25 cluster lentiviral vectormiR106b-25 cluster lentiviral vectormiR 106b-25 cluster lentiviral vectormiR-106b-25 overexpressing lentivirusmiR106b-25 overexpressing lentivirusmiR 106b-25 overexpressing lentivirus
02
Targets
Bcl-2 homologous antagonist/killer 1 (BAK1) mRNABcl-2-associated X protein mRNA (BAX mRNA)BTG2 (B-cell translocation gene 2)Caspase-7 mRNA (CASP7 mRNA)Cyclin-dependent kinase inhibitor 1A (CDKN1A) mRNABAKBAX (Apoptosis regulator BAX)CASP7 (Caspase-7)CDKN1A (Cyclin-dependent kinase inhibitor 1A)TP73 (Tumor protein p73)
Beyond the preview
Go deeper on miR-106b-25 lentiviral vector.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-106b-25 lentiviral vector.